BamSEC and AlphaSense Join Forces
Learn More

Evommune Inc. – Material Contracts

NYSE: EVMN    
Share price (8/12/26): $14.12    
Market cap (8/12/26): $512 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.4
from S-1/A 14 pages Evommune, Inc. 2025 Employee Stock Purchase Plan Adopted by the Board of Directors: October 9, 2025 Approved by the Stockholders: October 16, 2025
12/34/56
EX-10.3(B)
from S-1/A 18 pages Evommune, Inc. Stock Option Grant Notice
12/34/56
EX-10.3(A)
from S-1/A 34 pages Evommune, Inc. 2025 Equity Incentive Plan Adopted by the Board of Directors: October 9, 2025 Approved by the Stockholders: October 16, 2025
12/34/56
EX-10.17
from S-1 23 pages Office Lease
12/34/56
EX-10.16
from S-1 63 pages ***Certain Identified Information Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) of the Type That the Registrant Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[***]”) in This Exhibit.*** License Agreement
12/34/56
EX-10.15
from S-1 72 pages ***Certain Identified Information Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) of the Type That the Registrant Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[***]”) in This Exhibit.*** Sublicense Agreement
12/34/56
EX-10.14
from S-1 70 pages ***Certain Identified Information Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) of the Type That the Registrant Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[***]”) in This Exhibit.*** Sublicense Agreement
12/34/56
EX-10.13
from S-1 70 pages ***Certain Identified Information Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) of the Type That the Registrant Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[***]”) in This Exhibit.*** License, Development and Commercialization Agreement Dated as of December 17, 2020 by and Between Dermira, Inc. and Evommune, Inc
12/34/56
EX-10.12
from S-1 15 pages Evommune, Inc. Stock Appreciation Right Grant Notice
12/34/56
EX-10.11
from S-1 18 pages Employment Agreement
12/34/56
EX-10.10
from S-1 18 pages Employment Agreement
12/34/56
EX-10.9
from S-1 24 pages Employment Agreement
12/34/56
EX-10.8
from S-1 18 pages Employment Agreement
12/34/56
EX-10.7
from S-1 2 pages Amendment to Employment Agreement
12/34/56
EX-10.6
from S-1 23 pages Employment Agreement
12/34/56
EX-10.5
from S-1 23 pages Employment Agreement
12/34/56
EX-10.2(B)
from S-1 93 pages Evommune, Inc. 2020 Stock Plan Notice of Stock Option Grant
12/34/56
EX-10.2(A)
from S-1 19 pages Evommune, Inc. 2020 Stock Plan Adopted on May 6, 2020
12/34/56